Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls
The deals will bolster Takeda’s ADC portfolio, which the company now considers a key modality focus within its oncology business.

The deals will bolster Takeda’s ADC portfolio, which the company now considers a key modality focus within its oncology business.
During HUAWEI CONNECT 2025, Leo Chen, Senior Vice President, President of Enterprise Sales, Huawei, emphasised the focus is on how to harness AI’s full potential.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil
Oxford University and Ellison Institute link for AI vaccine research